Business Insider's July 30 virtual event features executives talking about procurement innovation strategies. The panel ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...

As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. | As summer began and ...

Risks to BMY include potential for tariffs to raise costs of drugs manufactured outside of the U.S. Moreover, drug pricing ...

After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. | After several PD ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with AUGTYRO and for 2 months following ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Ashwin Kishtagari, MD, of Vanderbilt University Medical Center in Nashville, summarizes 7 studies presented at the EHA 2025 Congress.

Bristol-Myers Squibb is testing MORAb-202 in a Phase 2 trial to challenge traditional chemotherapy for platinum-resistant ...